2017
DOI: 10.1016/j.vetmic.2017.04.012
|View full text |Cite|
|
Sign up to set email alerts
|

Antimicrobial susceptibility monitoring of Mycoplasma hyopneumoniae and Mycoplasma bovis isolated in Europe

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
49
2

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 44 publications
(63 citation statements)
references
References 33 publications
12
49
2
Order By: Relevance
“…Also, Andersen and others [25], described the presence of alternative bacterial resistance mechanisms for tylosin in comparison to tylvalosin, which can explain the differences in MIC values between members of the 16membered ring class of macrolides. The tylosin and tilmicosin MIC values were in agreement with those found in M. hyosynoviae [10], M. hyorhinis [12] and M. hyopneumoniae [17,23]. Based on our data, the macrolides could still be utilised as first-line antimicrobial treatment for the control of mycoplasma disease in pigs.…”
Section: Discussionsupporting
confidence: 85%
See 1 more Smart Citation
“…Also, Andersen and others [25], described the presence of alternative bacterial resistance mechanisms for tylosin in comparison to tylvalosin, which can explain the differences in MIC values between members of the 16membered ring class of macrolides. The tylosin and tilmicosin MIC values were in agreement with those found in M. hyosynoviae [10], M. hyorhinis [12] and M. hyopneumoniae [17,23]. Based on our data, the macrolides could still be utilised as first-line antimicrobial treatment for the control of mycoplasma disease in pigs.…”
Section: Discussionsupporting
confidence: 85%
“…Felde et al [22] described tulathromycin MIC 90 values of 1 and 4 μg/ml, 1-4 two-fold dilutions higher to those observed for tylvalosin after analysing Central European M. hyopneumoniae isolates. Conversely, Klein et al [23] described MIC 90 values for tulathromycin of 0.004 μg/ml, after analysing 50 European M. hyopneumoniae isolates, however, the authors did not include tylvalosin in their analysis. In addition, decreased susceptibility to tylosin and tilmicosin has been previously described in European M. hyosynoviae and M. hyopneumoniae isolates [10,24].…”
Section: Discussionmentioning
confidence: 99%
“…The susceptibility to valnemulin and tiamulin may have decreased in the period 1997 (Hannan et al, 1997) to 2013 (Tavio et al, 2014;Thongkamkoon et al, 2013). However, taken together, acquired antimicrobial resistance does currently not seem to constitute a major problem for treatment of M. hyopneumoniae infections (Klein et al, 2017), although the situation may be different for other bacteria complicating these infections. Finally, within a farm, strains with differences in antibiotic susceptibility may coexist (Thongkamkoon et al, 2013).…”
Section: Therapeuticsmentioning
confidence: 99%
“…Mycoplasma hyopneumoniae is intrinsically resistant to antibiotics which interfere with the polymerization of cell wall precursors, such as beta‐lactam antibiotics and to polymyxins, 14‐membered ring macrolides (such as oleandomycin and erythromycin), trimethoprim and sulfonamides. In vitro , acquired resistance has been documented for tetracyclines, 15‐membered ring macrolides (tulathromycin, gamithromycin), 16‐membered ring macrolides (tylosin, tilmicosin), lincosamides (lincomycin) and fluoroquinolones (Felde, Kreizinger, Sulyok, Hrivnak, et al, ; Felde, Kreizinger, Sulyok, Marton, et al, ; Klein et al, ; Tavio, Poveda, Assunção, Ramírez, & Poveda, ; Vicca et al, ; Vicca et al, ). It was shown that mutations in the 23S rRNA gene were responsible for resistance to macrolides and lincosamides (Stakenborg et al, ).…”
Section: Mycoplasma Hyopneumoniae Variabilitymentioning
confidence: 99%